Clinical Trial: Phase 3 DR10624 vs Placebo in Subjects With Severe Hypertriglyceridemia on Stable Lipid Therapy

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07693777) titled 'Phase 3 DR10624 vs Placebo in Subjects With Severe Hypertriglyceridemia on Stable Lipid Therapy' on July 01.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG). Eligible participants have persistently elevated fasting triglycerides despite stable background lipid-lowering therapy. Subjects will be randomized at a 2:2:1 ratio to three treatment arms: DR10624 low dose, DR10624 high dose, or matching placebo, receiving weekly subcutaneous injections f...